C07F9/50

Tri-(adamantyl)phosphines and applications thereof

In one aspect, phosphine compounds comprising three adamantyl moieties (PAd.sub.3) and associated synthetic routes are described herein. Each adamantyl moiety may be the same or different. For example, each adamantyl moiety (Ad) attached to the phosphorus atom can be independently selected from the group consisting of adamantane, diamantane, triamantane and derivatives thereof. Transition metal complexes comprising PAd.sub.3 ligands are also provided for catalytic synthesis including catalytic cross-coupling reactions.

Raw material composition for polyisocyanurate and method for producing polyisocyanurate

A polyisocyanurate raw material composition containing a polyfunctional isocyanate, a compound (I) represented by general formula (I) shown below, and an epoxy compound. In general formula (I), each of R.sup.1 to R.sup.5 represents a hydrogen atom, an alkoxy group of 1 to 10 carbon atoms, an alkyl group of 2 to 10 carbon atoms (or an alkyl group of 1 to 10 carbon atoms in the case of R.sup.3 to R.sup.5), an aryl group of 6 to 12 carbon atoms, an amino group, a monoalkylamino group of 1 to 10 carbon atoms, a dialkylamino group of 2 to 20 carbon atoms, a carboxy group, a cyano group, a fluoroalkyl group of 1 to 10 carbon atoms, or a halogen atom (provide that R.sup.1 and R.sup.2 are not both hydrogen atoms). ##STR00001##

TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Efficient phosphorous stabilizers based on diphenylamine and heterocyclic diphenylamine derivatives

The present invention relates to the use of efficient phosphorous substances, in particular based on diphenylamine and heterocyclic diphenylamine derivatives as stabilizers for organic materials, in particular for plastic materials, against oxidative, thermal and/or actinic degradation. The present invention additionally relates to an organic material that has been correspondingly stabilized as described above. The invention further relates to a method of stabilizing organic materials and to specific stabilizers.

Pincer-type ligand having acridane structure and metal complex using the same

Disclosed are a pincer-type ligand having a structurally rigid acridane structure and a metal complex consisting of the pincer-type ligand and a metal bound to each other, and exhibiting high reactivity and stability during a variety of bonding activation reactions. T-shaped complexes can be prepared from .sup.acriPNP(4,5-bis(diisopropylphosphino)-2,7,9,9-tetramethyl-9H-acridin-10-ide), which is a pincer-type PNP ligand having an acridane structure, and metal complexes, which can be structurally rigid and thus exhibit excellent reactivity and stability based on minimized structural change thereof, can be prepared by introducing an acridane structure into the backbone thereof. The PNP ligand is structurally stable and has novel chemical properties, as compared to conventional similar ligands, and thus can be utilized in a wide range of catalytic reactions and material chemistry.

Method for manufacturing catalyst liquid
11628430 · 2023-04-18 · ·

There is provided a method for producing a catalyst liquid containing a Group 6 to 11 transition metal catalyst in which the transition metal catalyst can be prevented from being blackened during storage, the method including performing addition of an alkenyl compound and addition of a phosphorus ligand, and then performing addition of a Group 6 to 11 transition metal catalyst

Method for Preparing L-Glufosinate

Provided are a method for preparing L-glufosinate and the intermediate compounds of formula (V) and formula (III).

TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF
20230158480 · 2023-05-25 ·

In one aspect, phosphine compounds comprising three adamantyl moieties (PAd.sub.3) and associated synthetic routes are described herein. Each adamantyl moiety may be the same or different. For example, each adamantyl moiety (Ad) attached to the phosphorus atom can be independently selected from the group consisting of adamantane, diamantane, triamantane and derivatives thereof. Transition metal complexes comprising PAd.sub.3 ligands are also provided for catalytic synthesis including catalytic cross-coupling reactions.

Process for preparing methyl phosphinic acid butyl ester

The present subject matter provides a safe alternative for producing an important intermediate useful for preparing the herbicide glufosinate, without need for chlorine components in the manufacturing process. In particular, a process for preparing alkyl phosphinic aid alkyl ester is provided, including the step of alkylating alkyl phosphinic acid ester in a non-polar solvent in the same apparatus as used to first produce the alkyl phosphinic acid ester, and without isolating the alkyl phosphinic acid ester before the alkylation step is conducted. More specifically, a process is presented for preparing methyl phosphinic acid butyl ester, by alkylating butyl phosphinic acid ester in a non-polar solvent, in the same apparatus as used previously to first produce the butyl phosphinic acid ester and without isolating the butylphosphinic acid ester before alkylation.

CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE

Provided are a condensed cyclic compound represented by Formula 1, an organic light-emitting device including the same, and an electronic apparatus including the organic light-emitting device.

##STR00001##

The detailed description of Formula 1 is the same as described in the present specification.